Objective: The study aimed to investigate the role of chemokine (C-C motif) ligand 18 (CCL18) in the progression of urothelial carcinoma (UC) after renal transplants (RT). Methods: Tissues were collected from 60 patients with UC in which 24 were after RT. The tissues were all obtained from patients after radical cystectomy. Expression levels of CCL18 were examined by immunohistochemistry, RT-polymerase chain -reaction (RT-PCR), and quantitative RT-PCR, respectively. WST-1 assay was performed to determine proliferative capacity of UC cells. Migration and invasion of UC cells were analyzed by the using of chemotaxis and Transwell system. Western blotting was applied to assess the activation of PI3K-mTOR (Mammalian Target of Rapamycin) signaling. Results: Compared to normal urothelial tissues, the expression levels of CCL18 were significantly increased in tumors of UC, and even more in tumors of UC after RT. Ectopic expression of CCL18 efficiently enhanced the proliferation of UC cells and moreover, exacerbated the migration and invasion of UC cells. Furthermore, overexpressed CCL18 increased the phosphorylation of PI3K, Akt, and mTOR in UC cells, suggesting the hyperactivation of PI3K/Akt/mTOR signaling. Conclusions: The results demonstrate the critical role of CCL18 in the progression of UC, especially in receipt with RT. Our study indicates that CCL18 could serve as a biomarker and therapeutic target in diagnosis of recipients with UC after RT.

Keywords:
CC chemokine ligand 18, PI3K-mTOR signaling, Urothelial carcinoma, Renal transplantation
1.
Zaza G, Dalla Gassa A, Felis G, et al: Impact of maintenance immunosuppressive therapy on the fecal microbiome of renal transplant recipients: comparison between an everolimus- and a standard tacrolimus-based regimen. PLoS One 2017; 12:e0178228.
2.
Birkeland SA, Storm HH, Lamm LU, et al: Cancer risk after renal transplantation in the Nordic countries, 1964–1986. Int J Cancer 1995; 60: 183–189.
3.
Villeneuve PJ, Schaubel DE, Fenton SS, et al: Cancer incidence among Canadian kidney transplant recipients. Am J Transplant 2007; 7: 941–948.
4.
Kasiske BL, Snyder JJ, Gilbertson DT, et al: Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905–913.
5.
Feng WW, Wang TN, Chen HC, et al: Malignancies after renal transplantation in southern Taiwan: experience in one centre. BJU Int 2007; 99: 825–829.
6.
Li XB, Xing NZ, Wang Y, et al: Transitional cell carcinoma in renal transplant recipients: a single center experience. Int J Urol 2008; 15: 53–57.
7.
Penn I: Malignancy. Surg Clin North Am 1994; 74: 1247–1257.
8.
Zhang A, Shang D, Zhang J, et al: A retrospective review of patients with urothelial cancer in 3,370 recipients after renal transplantation: a single-center experience. World J Urol 2015; 33: 713–717.
9.
Tsicopoulos A, Chang Y, Ait Yahia S, et al: Role of CCL18 in asthma and lung immunity. Clin Exp Allergy 2013; 43: 716–722.
10.
Schutyser E, Richmond A, Van Damme J: Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol 2005; 78: 14–26.
11.
Chen J, Yao Y, Gong C, et al: CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 2011; 19: 541–555.
12.
Ploenes T, Scholtes B, Krohn A, et al: CC-chemokine ligand 18 induces epithelial to mesenchymal transition in lung cancer A549 cells and elevates the invasive potential. PLoS One 2013; 8:e53068.
13.
Yuan L, Wan J, Huang C, et al: Evaluation of serum CCL18 as a potential biomarker for ovarian cancer. Cancer Biomarkers 2017; 21: 97–104.
14.
Leung SY, Yuen ST, Chu KM et al: Expression profiling identifies chemokine (C-C motif) ligand 18 as an independent prognostic indicator in gastric cancer. Gastroenterology 2004; 127: 457–469.
15.
Catusse J, Wollner S, Leick M, et al: Attenuation of CXCR4 responses by CCL18 in acute lymphocytic leukemia B cells. J Cell Physiol 2010; 225: 792–800.
16.
Li HY, Cui XY, Wu W, et al: Pyk2 and Src mediate signaling to CCL18-induced breast cancer metastasis. J Cell Biochem 2014; 115: 596–603.
17.
Islam SA, Ling MF, Leung J, et al: Identification of human CCR8 as a CCL18 receptor. J Exp Med 2013; 210: 1889–1898.
18.
Zohny SF, Fayed ST: Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer. Med Oncol 2010; 27: 1246–1253.
19.
Wang Q, Li D, Zhang W, Tang B, et al: Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses. Int J Biol Markers 2011; 26: 262–273.
20.
Jacobs BL, Lee CT, Montie JE: Bladder cancer in 2010: how far have we come? CA Cancer J Clin 2010; 60: 244–272.
21.
Shang D, Zheng T, Zhang J, et al: Profiling of mRNA and long non-coding RNA of urothelial cancer in recipients after renal transplantation. Tumor Biol 2016; 37: 12673-12684.
22.
Urquidi V, Kim J, Chang M, et al: CCL18 in a multiplex urine-based assay for the detection of bladder cancer. PLoS One 2012; 7:e37797.
23.
Miyake M, Ross S, Lawton A, et al: Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection. BMC Urol 2013; 13: 42–52.
24.
Shang D, Liu Y, Yang P, et al: TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor. Urology 2012; 79: 966.e1–e7.
25.
Melchior S, Franzaring L, Shardan A, et al: Urological de novo malignancy after kidney transplantation: a case for the urologist. J Urol 2011; 185: 428–432.
26.
Galve ML, Cuervas-Mons V, Figueras J, et al: Incidence and outcome of de novo malignancies after liver transplantation. Transplant Proc 1999; 31: 1275–1277.
27.
Matsuo Y, Takeyama H, Guha S: Cytokine network: new targeted therapy for pancreatic cancer. Curr Pharm Des 2012; 18: 2416–2419.
28.
Meng F, Li W, Li C, et al: CCL18 promotes epithelial-mesenchymal transition, invasion and migration of pancreatic cancer cells in pancreatic ductal adenocarcinoma. Int J Oncol 2015; 46: 1109–1120.
29.
Lin Z, Li W, Zhang H, et al: CCL18/PITPNM3 enhances migration, invasion, and EMT through the NF-kappaB signaling pathway in hepatocellular carcinoma. Tumor Biol 2016; 37: 3461–3468.
30.
Wang H, Liang X, Li M, et al: Chemokine (CC motif) ligand 18 upregulates Slug expression to promote stem-cell like features by activating the mammalian target of rapamycin pathway in oral squamous cell carcinoma. Cancer Sci 2017; 108: 1584–1593.
31.
Chiarini F, Evangelisti C, McCubrey JA, et al: Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci 2015; 36: 124–135.
32.
Xia P, Xu XY: PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. Am J Cancer Res 2015; 5: 1602–1609.
33.
Li HZ, Xia M, Han Y, et al: De novo urothelial carcinoma in kidney transplantation patients with end-stage aristolochic acid nephropathy in China. Urol Int 2009; 83: 200–205.
34.
Stiborová M, Frei E, Hodek P, et al: Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. Int J Cancer 2005; 113: 189–197.
35.
Stiborová M, Frei E, Schmeiser HH, et al: Mechanisms of enzyme-catalyzed reduction of two carcinogenic nitro-aromatics, 3-nitrobenzanthrone and aristolochic acid I: eperimental and theoretical approaches. Int J Mol Sci 2014; 15: 10271–10295.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.